Galmed Pharma (GLMD) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $274 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Cintas beats estimates but stock edges lower
- General Mills beats estimates as cost savings offset volumes
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
